These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 25524713

  • 1. TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy.
    Hernández-Romero D, Jover E, Martínez CM, Andreu-Cayuelas JM, Orenes-Piñero E, Romero-Aniorte AI, Casas T, Cánovas S, Montero-Argudo JA, Valdés M, de la Morena G, Marín F.
    Eur J Clin Invest; 2015 Feb; 45(2):179-86. PubMed ID: 25524713
    [Abstract] [Full Text] [Related]

  • 2. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vicente V.
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [Abstract] [Full Text] [Related]

  • 3. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling.
    Saura D, Marín F, Climent V, González J, Roldán V, Hernández-Romero D, Oliva MJ, Sabater M, de la Morena G, Lip GY, Valdés M.
    Int J Clin Pract; 2009 Oct; 63(10):1465-71. PubMed ID: 19769703
    [Abstract] [Full Text] [Related]

  • 4. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC.
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [Abstract] [Full Text] [Related]

  • 5. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.
    Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C.
    Am Heart J; 2005 Dec; 150(6):1228-32. PubMed ID: 16338263
    [Abstract] [Full Text] [Related]

  • 6. Relationships between P wave dispersion, atrial electromechanical delay, left atrial remodeling, and NT-proBNP levels, in patients with hypertrophic cardiomyopathy.
    Tuluce K, Ozerkan F, Yakar Tuluce S, Yavuzgil O, Gurgun C, Bilgin M, Kahya Eren N, Kocabas U, Nalbantgil S, Soydas Cinar C.
    Cardiol J; 2015 Dec; 22(1):94-100. PubMed ID: 24671901
    [Abstract] [Full Text] [Related]

  • 7. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy.
    Montoro-García S, Hernández-Romero D, Jover E, García-Honrubia A, Vilchez JA, Casas T, Martínez P, Climent V, Caballero L, Valdés M, Marín F.
    Eur J Intern Med; 2012 Mar; 23(2):169-74. PubMed ID: 22284249
    [Abstract] [Full Text] [Related]

  • 8. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy.
    Hsu A, Kittleson MD, Paling A.
    J Vet Cardiol; 2009 May; 11 Suppl 1():S63-70. PubMed ID: 19395334
    [Abstract] [Full Text] [Related]

  • 9. Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance.
    Gawor M, Śpiewak M, Kubik A, Wróbel A, Lutyńska A, Marczak M, Grzybowski J.
    Biomarkers; 2018 Nov; 23(7):676-682. PubMed ID: 29737871
    [Abstract] [Full Text] [Related]

  • 10. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
    Payá E, Marín F, González J, Gimeno JR, Feliu E, Romero A, Ruiz-Espejo F, Roldán V, Climent V, de la Morena G, Valdés M.
    J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
    [Abstract] [Full Text] [Related]

  • 11. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy.
    Wu G, Liu J, Wang S, Yu S, Zhang C, Wang D, Zhang M, Yang Y, Kang L, Zhao S, Hui R, Zou Y, Wang J, Song L.
    Heart; 2021 Oct; 107(19):1576-1583. PubMed ID: 33361398
    [Abstract] [Full Text] [Related]

  • 12. NT-proBNP changes, oxidative stress, and energy status of hypertrophic myocardium following ischemia/reperfusion injury.
    Scolletta S, Carlucci F, Biagioli B, Marchetti L, Maccherini M, Carlucci G, Rosi F, Salvi M, Tabucchi A.
    Biomed Pharmacother; 2007 Oct; 61(2-3):160-6. PubMed ID: 17350221
    [Abstract] [Full Text] [Related]

  • 13. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats.
    Wess G, Daisenberger P, Mahling M, Hirschberger J, Hartmann K.
    Vet Clin Pathol; 2011 Jun; 40(2):237-44. PubMed ID: 21434959
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Hernández-Romero D, Orenes-Piñero E, García-Honrubia A, Climent V, Romero-Aniorte AI, Martínez CM, García-Bautista M, Martínez M, Feliu E, González J, Cánovas S, Montero-Argudo JA, Valdés M, Marín F.
    J Intern Med; 2015 Jul; 278(1):50-8. PubMed ID: 25476756
    [Abstract] [Full Text] [Related]

  • 16. Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy.
    Cambronero F, Vilchez JA, García-Honrubia A, Ruiz-Espejo F, Moreno V, Hernández-Romero D, Bonacasa B, González-Conejero R, de la Morena G, Martínez P, Climent V, Valdés M, Marín F.
    Thromb Res; 2010 Jul; 126(1):e46-50. PubMed ID: 20156645
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.
    Efthimiadis GK, Hitoglou-Makedou A, Giannakoulas G, Mitakidou A, Karamitsos T, Karvounis H, Mochlas S, Styliadis I, Stefanidis H, Parcharidis G, Louridas G.
    Heart Vessels; 2007 Sep; 22(5):322-7. PubMed ID: 17879024
    [Abstract] [Full Text] [Related]

  • 18. Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy.
    Romero-Puche A, Marín F, González-Carrillo J, García-Honrubia A, Climent V, Feliu E, Ruiz-Espejo F, Payá E, Gimeno-Blanes JR, de la Morena G, Valdés-Chavarri M.
    Rev Esp Cardiol; 2008 Aug; 61(8):853-60. PubMed ID: 18684368
    [Abstract] [Full Text] [Related]

  • 19. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy.
    Coats CJ, Gallagher MJ, Foley M, O'Mahony C, Critoph C, Gimeno J, Dawnay A, McKenna WJ, Elliott PM.
    Eur Heart J; 2013 Aug; 34(32):2529-37. PubMed ID: 23455360
    [Abstract] [Full Text] [Related]

  • 20. Time and age dependent decrease of NT-proBNP after septal myectomy in hypertrophic obstructive cardiomyopathy.
    Cui H, Wu X, Wang S, Tang B, Zhu C, Chen H, Zhou X, Wu R, Yu Q, Huang X.
    Clin Chem Lab Med; 2017 Aug 28; 55(10):1614-1620. PubMed ID: 28301315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.